Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study

References

• Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 2014;25:1439-43
   PubMed Web of Science ®Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005;16:155-62
   PubMed Web of Science ®Google Scholar
• De Laet C, Kanis JA, Odén A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005;16:1330-8
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57
   PubMed Web of Science ®Google Scholar
• Paul TL, Kerrigan J, Kelly AM, et al. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988;259:3137-41
   PubMed Web of Science ®Google Scholar
• Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990;113:265-69
   PubMed Web of Science ®Google Scholar
• Fraser SA, Anderson JB, Smith DA, Wilson GM. Osteoporosis and fractures following thyrotoxicosis. Lancet 1971;297:981-3
   Google Scholar
• Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med 1998;128:386-94
   PubMed Web of Science ®Google Scholar
• Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991;72:1184-8
   PubMed Web of Science ®Google Scholar
• Franklyn JA, Betteridge J, Daykin J, et al. Long-term thyroxine treatment and bone mineral density. Lancet 1992;340:9-13
   PubMed Web of Science ®Google Scholar
• Wang LY, Smith AW, Palmer FL, et al. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid 2015;25:300-7
   PubMed Web of Science ®Google Scholar
• Larijani B, Gharibdoost F, Pajouhi M, et al. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women. J Clin Pharm Ther 2004;29:1-5
   PubMed Web of Science ®Google Scholar
• Jódar E, Begoña López M, García L, et al. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. Osteoporos Int 1998;8:311-16
   PubMed Web of Science ®Google Scholar
• McDermott MT, Perloff JJ, Kidd GS. A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer. Calcif Tissue Int 1995;56:521-5
   PubMed Web of Science ®Google Scholar
• Quan ML, Pasieka JL, Rorstad O. Bone mineral density in well‐differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol 2002;79:62-70
   PubMed Web of Science ®Google Scholar
• Reverter JL, Holgado S, Alonso N, et al. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocr Relat Cancer 2005;12:973-81
   PubMed Web of Science ®Google Scholar
• Toivonen J, Tähtelä R, Laitinen K, et al. Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 1998;138:667-73
   PubMed Web of Science ®Google Scholar
• Lee MY, Park JH, Bae KS, et al. Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer. Ann Surg Treat Res 2014;86:55-60
   PubMed Web of Science ®Google Scholar
• Mikosch P, Jauk B, Gallowitsch HJ, et al. Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism. Thyroid 2001;11:257-63
   PubMed Web of Science ®Google Scholar
• Heijckmann AC, Huijberts MS, Geusens P, et al. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol 2005;153:23-9
   PubMed Web of Science ®Google Scholar
• Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 2011;150:1250-7
   PubMed Web of Science ®Google Scholar
• Bassett JH, Williams GR. The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab 2003;14:356-64
   PubMed Web of Science ®Google Scholar
• Tuchendler D, Bolanowski M. The influence of thyroid dysfunction on bone metabolism. Thyroid Res 2014;7:12
   PubMedGoogle Scholar
• Williams GR. Thyroid hormone actions in cartilage and bone. Eur Thyroid J 2013;2:3-13
   PubMedGoogle Scholar
• Baliram R, Sun L, Cao J, et al. Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J Clin Invest 2012;122:3737-41
   PubMed Web of Science ®Google Scholar
• Bauer DC, Ettinger B, Nevitt MC, Stone KL; Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001;134:561-8
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133
   PubMed Web of Science ®Google Scholar